Event-Driven Stocks

scPharmaceuticals Inc.

SCPH

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 5 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$36.3M$13.6M————
Operating income−$64.8M−$55.4M−$36.2M−$25.8M−$29.9M−$32.9M
Net income−$85.1M−$54.8M−$36.8M−$28.0M−$32.2M−$33.0M
Total assets$107.5M$94.5M$124.2M$79.0M$109.0M$77.3M
Total liabilities$94.2M$57.3M$51.8M$22.6M$26.9M$25.9M
Equity$13.3M$37.2M$72.4M$56.5M$82.2M$51.4M
EPS (diluted)$-1.91$-1.42$-1.30$-1.02——
Shares out.36.1M35.8M27.4M27.4M21.0M18.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−178.3%
Net margin
−234.4%
Return on equity
−639.2%
Return on assets
−79.2%
Return on capital (ROCE)
−69.9%
Liabilities / assets
87.6%
Debt / equity
7.07×
Book value / share
$0.37
Revenue growth (YoY)
167.3%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-9.46distress
Accruals / assets
−13.6%clean
Beneish M-Score
-1.69elevated
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • FUROSCIXOct 7, 2022

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Sep 30, 20251.1M1.0+34.8%
Sep 15, 2025811,7741.0+16.9%
Aug 29, 2025694,5671.0-48.2%
Aug 15, 20251.3M3.3+32.4%
Jul 31, 20251.0M3.0-35.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)